QUOTE AND NEWS
Motley Fool  May 9  Comment 
Rising global demand for Invisalign has propelled shares to new highs, and there's plenty of room left to grow.
Motley Fool  Apr 28  Comment 
Despite a down market, these stocks were up. Find out why.
Motley Fool  Apr 28  Comment 
Strong first-quarter sales and earnings are spiking interest in the maker of Invisalign.
Benzinga  Apr 28  Comment 
Baird boosted the price target on Align Technology, Inc. (NASDAQ: ALGN) from $105 to $155. Align Technology shares closed at $120.09 on Thursday. Needham & Company lowered the price target for Gigamon Inc (NYSE: GIMO) from $38 to $34....
MarketWatch  Apr 27  Comment 
Align Technology Inc. shares rallied in the extended session Thursday after the maker of Invisalign braces issued a forecast above Wall Street estimates. Align shares surged 13% to $135.75 after hours. The company forecast earnings of 71 cents to...
Motley Fool  Apr 27  Comment 
The orthodontic-device maker shattered its previous all-time high revenue mark as demand soared for its clear dental aligners.
Forbes  Apr 25  Comment 
Align Technology, maker of braces alternative Invisalign, has a lot to smile about. In 2016, sales hit $1 billion for the first time. But one of its biggest advantages – its arsenal of more than 400 U.S. and 300 foreign-issued patents – is...
Motley Fool  Apr 9  Comment 
Buy-and-hold investing can make you rich.




RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS

Align Technology, Inc., founded in 1997, is engaged in the design, manufacture, and marketing of Invisalign, a proprietary system for treating malocclusion, or crooked teeth. The Invisalign product has two components, ClinCheck and Aligners. ClinCheck is an Internet-based application that allows dental professionals to simulate treatment in three dimensions, by modeling two-week stages of tooth movement. Aligners are thin, clear-plastic, removable dental appliances that are manufactured in a series to correspond to each two-week stage of the ClinCheck simulation. Aligners are customized to perform the treatment prescribed for an individual patient by dental professionals using ClinCheck. Invisalign is approved to treat patients, with any type of malocclusion, with mature upper and lower tooth structures. The company voluntarily restricts the use of Invisalign to adults and adolescents with immature structures. Typically, permanent structures occur in the later-teen years. Align does not treat children whose teeth and jaws are still developing, as the effectiveness of Invisalign relies on the company's ability to accurately predict the movement of teeth over the course of treatment. Based on its clinical studies to date, Align recommends that dental professionals use Invisalign as a complete treatment for a range of malocclusions, and as a component of treatment for severe malocclusions.


Internationally, the company operates in the regions of Europe, Asia/Pacific, and Latin America. At the end of 2007, sales in the domestic orthodontist channel represented 30% of total revenues, while sales in the domestic general practitioner (GP) channel represented 46%, and the international channel represented 20%. The remaining 5% came from education training and other revenues.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki